First-Line Pharmacotherapy for Newly Diagnosed Hypertension

Evidence-Based Drug Class Selection

The World Health Organization provides strong evidence (high quality) that all four major drug classes (thiazide or thiazide-like diuretics, ACE inhibitors, angiotensin receptor blockers, or long-acting dihydropyridine calcium channel blockers) are equally acceptable as first-line agents for newly diagnosed hypertension 1

For Black patients, the American Heart Association recommends starting with either a thiazide diuretic or a calcium channel blocker, as these are more effective than ACE inhibitors in this population 2, 3, 4
For patients with albuminuria, the American Diabetes Association and the National Kidney Foundation recommend ACE inhibitors or ARBs as mandatory first-line therapy 2, 3
For patients with established coronary artery disease, the American College of Cardiology recommends ACE inhibitors or ARBs as the initial choice 2, 3
For patients aged 55 or older, the European Society of Cardiology recommends CCBs or diuretics as generally more effective 2
For patients younger than 55 and white, the American Heart Association suggests ACE inhibitors or ARBs may be more effective initially 2

For Stage 2 Hypertension, the American Heart Association recommends initiating combination therapy with two drugs from different classes, preferably as a single-pill combination 1, 2, 3
Combination therapy improves adherence and achieves blood pressure control more rapidly, according to the European Society of Hypertension 1, 3

The American Heart Association advises against combining ACE inhibitors with ARBs, as this dual RAS blockade increases adverse effects without additional benefit 2, 3
The European Society of Cardiology recommends avoiding beta-blockers as first-line therapy unless specific indications exist (prior MI, active angina, heart failure with reduced ejection fraction) 2, 3

The American Heart Association recommends a standard target of <140/90 mmHg for all patients without comorbidities 1
The American College of Cardiology recommends an intensive target of <130/80 mmHg for patients with known CVD (strong recommendation) 1
The European Society of Cardiology suggests considering <130 mmHg systolic for high-risk patients with diabetes, chronic kidney disease, or high CVD risk 1

The American Heart Association recommends monthly reassessment after initiation or medication changes until target BP achieved 1
The European Society of Hypertension recommends every 3-5 months once blood pressure is controlled 1